Search company, investor...

Predict your next investment

Memorial Sloan Kettering Cancer Center company logo
Corporation
HEALTHCARE | Medical Facilities & Services / Hospitals
mskcc.org

Investments

6

Portfolio Exits

2

Funds

1

Partners & Customers

10

About Memorial Sloan Kettering Cancer Center

Memorial Sloan Kettering Cancer Center is committed to patient care, research, and educational programs. Its education programs train future physicians and scientists.

Headquarters Location

1275 York Avenue

New York, New York, 10065,

United States

212-639-2000

Want to inform investors similar to Memorial Sloan Kettering Cancer Center about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Research containing Memorial Sloan Kettering Cancer Center

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Memorial Sloan Kettering Cancer Center in 1 CB Insights research brief, most recently on Jan 19, 2021.

Latest Memorial Sloan Kettering Cancer Center News

Q&A: Healthcare content producer Jon Cody

Jan 31, 2023

One of Cody’s latest projects is a docuseries, “A Life Worth Running,” about Peter Kirk, an acute myeloid leukemia survivor and CEO of Sermo. by Eric BergerAdded 55 minutes ago NEW YORK: Jon Cody had spent almost 15 years working in television and video streaming for companies such as Fox and Hulu when in 2021 he launched a movie company focused on a niche: health and healthcare. "There's so much information and misinformation out there [when people search for information on the internet]," Cody said. "If you did find a video that was interesting, it was often very clinical." His goal, he said, is "to bring Hollywood storytelling into healthcare." One of Cody's latest projects is a docuseries, "A Life Worth Running," about Peter Kirk, an acute myeloid leukemia survivor and the CEO of Sermo, which provides a social network for physicians. Only about 30% of U.S. adults with that cancer survive more than five years, according to Yale Medicine. The three-part series tells the story of Kirk almost dying from the double whammy of leukemia and double lung pneumonia, receiving a stem-cell transplant and deciding to run the New York City Marathon. We also see Cody, now cured of the disease, reach out to his donor and meet him. PRWeek conducted a phone interview with Cody to learn more about the series and his company. What made you decide that there was a need for a company that offered Hollywood storytelling to healthcare companies? Part of why we started it is personal. I have two sons who are on the Autism spectrum. Everyone starts healthcare with Dr. Google, and you're running down a YouTube rabbit hole of stuff where you don't know if it's good or bad. The more that you can plain-English health and healthcare, and the more that you can get beyond a simple doctor to trusted sources like nurses, like caregivers, like patients. We felt like it was a more powerful message to people seeking information." How does your company's business model work? Do healthcare organizations or companies pay you to produce films? Yeah, they do. Some pay us just to do what they want to do. Some will pay us on the sponsorship of things that we want to do as a studio, and then there's that middle ground, like with Sermo, where it's a pure co-production, where we are developing intellectual property together and co-owning the story and the ancillary content. You can imagine a story like this could be a scripted feature film. What do you think a film like this does for Sermo or Memorial Sloan Kettering Cancer Center? (Kirk recovered at Sloan Kettering and committed to donate $1 million to the hospital). We want to bring a little more awareness to who they are. It does raise the brand, and a lot of what we said to Sermo and Memorial Sloan Kettering is that you want to activate your talent. You actually have talent within that building. And, yes, some of them are on TikTok, but a lot of it is activating those people in a way where they are actually produced. And there's kind of a third angle: how do you use video for research purposes? You see a lot of public health grants go to medical research institutions, but they haven't yet used storytelling and video to improve outcomes. Is there a particular skill set or technique that is required to make healthcare films as compared to films about other industries or other sorts of entertainment movies? You need the appropriate people to make sure that there's medical accuracy, although that happens even on a show like "House." There are always consultants who play those roles, but I think ultimately the difference here for us is the voices of healthcare. A patient can speak in plain English, but you want to make sure that a medical professional — I don't want to say dumbs it down — but speaks on a level that the rest of us can understand. Subject Tags:

Memorial Sloan Kettering Cancer Center Investments

6 Investments

Memorial Sloan Kettering Cancer Center has made 6 investments. Their latest investment was in Blue Note Therapeutics as part of their Series A - II on September 9, 2021.

CBI Logo

Memorial Sloan Kettering Cancer Center Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/9/2021

Series A - II

Blue Note Therapeutics

$5.2M

Yes

5

6/1/2021

Series B

Subscribe to see more

$99M

Subscribe to see more

10

8/9/2019

Series D

Subscribe to see more

$99M

Subscribe to see more

10

2/21/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

2/13/2018

Series C

Subscribe to see more

$99M

Subscribe to see more

10

Date

9/9/2021

6/1/2021

8/9/2019

2/21/2018

2/13/2018

Round

Series A - II

Series B

Series D

Series C

Series C

Company

Blue Note Therapeutics

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$5.2M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

5

10

10

10

10

Memorial Sloan Kettering Cancer Center Portfolio Exits

2 Portfolio Exits

Memorial Sloan Kettering Cancer Center has 2 portfolio exits. Their latest portfolio exit was ORIC Pharmaceuticals on April 24, 2020.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

4/24/2020

IPO

$99M

Public

4

2/4/2018

Spinoff / Spinout

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/24/2020

2/4/2018

Exit

IPO

Spinoff / Spinout

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

4

10

Memorial Sloan Kettering Cancer Center Acquisitions

1 Acquisition

Memorial Sloan Kettering Cancer Center acquired 1 company. Their latest acquisition was Ralph Lauren Center for Cancer Care and Prevention on August 08, 2018.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

8/8/2018

$99M

Acquired

1

Date

8/8/2018

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired

Sources

1

Memorial Sloan Kettering Cancer Center Fund History

1 Fund History

Memorial Sloan Kettering Cancer Center has 1 fund, including Fiona and Stanley Druckenmiller Presidential Innovation Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

Fiona and Stanley Druckenmiller Presidential Innovation Fund

$100M

2

Closing Date

Fund

Fiona and Stanley Druckenmiller Presidential Innovation Fund

Fund Type

Status

Amount

$100M

Sources

2

Memorial Sloan Kettering Cancer Center Partners & Customers

10 Partners and customers

Memorial Sloan Kettering Cancer Center has 10 strategic partners and customers. Memorial Sloan Kettering Cancer Center recently partnered with Illuminare Biotechnologies on January 1, 2023.

Date

Type

Business Partner

Country

News Snippet

Sources

1/23/2023

Partner

United States

Illuminare Biotechnologies Announces First Participant Dosed in Phase I Study of Novel Nerve Visualization Investigational Fluorophore

The first-in-human clinical trial is being conducted at Memorial Sloan Kettering Cancer Center , along with collaborators from Illuminare Biotechnologies , in patients undergoing robot-assisted radical prostatectomy .

1

1/13/2023

Partner

United States

NYSNA: ‘It’s not over’ as agreements usher in improved staffing ratios, wages

The first phase of the partnership is expected to last throughout the year and will focus on physicians at MSK working with MediSys Health Network to enhance the onsite oncology program at Jamaica Hospital .

1

12/14/2022

Partner

Israel

NewStem Announces New Collaboration to Validate its Software Diagnostic Device for Two Oncology Indications and Two Therapies

`` Despite enormous progress over decades , resistance to anti-cancer drugs continues to be a major problem in treating cancer , the second-leading cause of death globally , '' said Ayelet Dilion-Mashiah , Chief Executive Officer of NewStem Ltd. `` We are excited to work with the MSK Innovation Hub in a collaboration that will bring together experts with the deepest expertise and a common goal to improve the lives of people with cancer . ''

2

12/14/2022

Partner

United States

Subscribe to see more

Subscribe to see more

10

11/21/2022

Vendor

United States

Subscribe to see more

Subscribe to see more

10

Date

1/23/2023

1/13/2023

12/14/2022

12/14/2022

11/21/2022

Type

Partner

Partner

Partner

Partner

Vendor

Business Partner

Country

United States

United States

Israel

United States

United States

News Snippet

Illuminare Biotechnologies Announces First Participant Dosed in Phase I Study of Novel Nerve Visualization Investigational Fluorophore

The first-in-human clinical trial is being conducted at Memorial Sloan Kettering Cancer Center , along with collaborators from Illuminare Biotechnologies , in patients undergoing robot-assisted radical prostatectomy .

NYSNA: ‘It’s not over’ as agreements usher in improved staffing ratios, wages

The first phase of the partnership is expected to last throughout the year and will focus on physicians at MSK working with MediSys Health Network to enhance the onsite oncology program at Jamaica Hospital .

NewStem Announces New Collaboration to Validate its Software Diagnostic Device for Two Oncology Indications and Two Therapies

`` Despite enormous progress over decades , resistance to anti-cancer drugs continues to be a major problem in treating cancer , the second-leading cause of death globally , '' said Ayelet Dilion-Mashiah , Chief Executive Officer of NewStem Ltd. `` We are excited to work with the MSK Innovation Hub in a collaboration that will bring together experts with the deepest expertise and a common goal to improve the lives of people with cancer . ''

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

2

10

10

Memorial Sloan Kettering Cancer Center Team

25 Team Members

Memorial Sloan Kettering Cancer Center has 25 team members, including current President, Paul A Marks.

Name

Work History

Title

Status

Paul A Marks

President

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Name

Paul A Marks

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Work History

Title

President

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Current

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.